Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrates significantly higher neutralizing antibody response against Omicron subvariants BA.4/5 compared to currently authorized booster
mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma
Moderna has completed regulatory submissions for mRNA-1273.214 in EU, UK, and Australia, expects to complete most remaining filings this week
Company simultaneously developing mRNA-1273.222, a bivalent candidate based on BA.4/5, consistent with recent FDA guidance
Read the full press release here.
Source : Moderna, Inc.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.